Consulting and PK/PD Modelling Services for Preclinical and Clinical Biotherapeutics Development
Mission
We support the translation of innovation into pharmacological concepts and therapies. We believe that the most innovative therapeutic ideas deserve the best development tools. We use Systems Pharmacology as a key tool to maximize the success of your preclinical program, clinical study or registration.
Services
Our services includes consultancy and implementation of systems pharmacology and PK/PD modelling for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, paediatric dose selection and dose / regimen finding studies.
Why choose us
Our methods have been successfully applied in global pharmaceutical companies with tangible results including patents. We have the unique tested expertise developing bi-specifics, antibody-drug conjugates, scFv’s, nanobodies, cell based therapies to provide tailored support for your program.
Partners
LYO-X is closely working with KinDyn Consulting and Integrated Biologix in order to provide fully integrated consultancy for preclinical and clinical development of biologics covering toxicology, pathology, CMC, bioanalysis, PK/PD, immunogenicity, and regulatory strategies.
LYO-X is partnering with Lixoft to provide you access to Monolix the scientifically and technologically most advanced software for preclinical and clinical data analysis.
LYO-X Kurzgesagt
Small Data Big Results
Learn more why Systems Pharmacology is a critical tool for the development of novel Biologics
-
Comprehensive mathematical model of the alternative complement pathway describing in vitro experimental- and clinical-data
October 7, 2020We recently published a comprehensive mathematical model of the alternative complement pathway in the PLOS Computational Biology journal. The model includes all known positive and negative regulators of the pathway and has been tested on a comprehensive set of in vitro experimental data and clinical data. As such its an … Read More
-
Population PK/PD Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation
June 5, 2020Glenzocimab (ACT017) is a humanized monoclonal antigen‐binding fragment (Fab) directed against the human platelet glycoprotein VI, a key receptor for collagen and fibrin that plays a major role in thrombus growth and stability. We developed a model to understand the PK/PD properties of this compound and to help with the … Read More
-
Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model
April 17, 2020Fabian Bernhard, Rajesh Odedra, Sylvie Sordello, Rossella Cardin, Samantha Franzoni, Cédric Charrier, Adam Belley, Peter Warn, Matthias Machacek, Philipp Knechtle Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance determinants. Enmetazobactam (formerly AAI101) is a novel ESBL inhibitor developed in combination with cefepime for empiric treatment of serious Gram-negative infections in … Read More
-
The Exposure Response Relationship of Enmetazobactam, Combined with Cefepime, is Best Described by f T > C T in a Murine Thigh Infection Model
October 4, 2019F. Berhard 1, M. Machacek 1, P. Warn 2, R. Odedra 2, S. Sordello 2, A. Belley 3, P. Knechtle 3 1 LYO-X Allschwil CH; 2 Evotec Cheshire UK; 3 Allecra Therapeutics Saint-Louis FR ASM-ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance • September 3-6, 2019 … Read More